By thorough analysis of diverse structures of published TGR5 agonists, a hypothetical ligand‐based pharmacophore model was built, and a new class of potent TGR5 agonists, based on the novel 3,4,5‐trisubstituted 4,5‐dihydro‐1,2,4‐oxadiazole core, was discovered by rational design. Three distinct synthetic methods for constructing 4,5‐dihydro‐1,2,4‐oxadiazoles and extensive structure–activity relationship
鉴于其在能量和
葡萄糖稳态中的介导作用,G蛋白偶联
胆汁酸受体1(TGR5)被认为是治疗2型糖尿病和其他代谢性疾病的潜在靶标。通过对已发表的TGR5激动剂的各种结构进行全面分析,建立了一个假设的基于
配体的药效团模型,并基于新型3,4,5-三取代的4,5-二
氢-1,2来开发了一类新型的强效TGR5激动剂。 ,4-恶二唑核是通过合理设计发现的。本文报道了三种不同的合成方法来构建4,5-二
氢-
1,2,4-恶二唑和广泛的结构-活性关系研究。化合物(R)-54 n,其结构是通过单晶X-射线衍射和量子
化学固态TDDFT-
ECD计算确定,显示出最好的效力,用
EC 50为1.4的n值中号朝向hTGR5。它在体外的有利特性值得进一步研究。